Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche
Key Highlights
- ➤MangoRx IP Holdings secured $2.5 million from two strategic investors.
- ➤Mangoceuticals (MGRX) received an initial $1.75 million investment tranche.
- ➤Investors will acquire a 25% membership interest in MangoRx IP Holdings.
- ➤Second $750,000 tranche is due by November 28, 2026.
- ➤Investment involves no issuance of MGRX shares, warrants, or parent securities.
Expert Statements
Jacob Cohen, Founder and Chief Executive Officer of Mangoceuticals
“We believe that this investment represents an important validation of the value we have built within MangoRx IP Holdings and provides us with additional capital to advance the next phase of commercialization, without issuing a single share of MGRX common stock.”
Jacob Cohen, Founder and Chief Executive Officer of Mangoceuticals
“We deliberately structured this investment at the subsidiary level to accomplish two key objectives: bring in strategic outside capital to help fund the commercialization of our intellectual property portfolio, while preserving the capital structure of Mangoceuticals and limiting dilution to our public shareholders.”
Jacob Cohen, Founder and Chief Executive Officer of Mangoceuticals
“We also believe that having strategic investors aligned with MangoRx IP further strengthens our position as we pursue potential licensing, distribution and other commercialization opportunities.”
Subsidiary-Level Investment Provides Capital to Advance Commercialization of the Company’s Antiviral Intellectual Property Portfolio with No Issuance of MGRX Common Stock
DALLAS, TEXAS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”), a company focused on developing, marketing, and selling health and wellness products through a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that its former wholly-owned subsidiary, MangoRx IP Holdings, LLC (“MangoRx IP”), has entered into subscription agreements with two strategic investors for an aggregate investment of $2.5 million directly into MangoRx IP, and has received the first tranche of $1.75 million due thereunder. Importantly, the investments are being made at the subsidiary level and do not involve the issuance of any shares of Mangoceuticals common stock, warrants or other securities of the publicly-traded parent company. Accordingly, the transactions do not increase the number of outstanding shares of Mangoceuticals or otherwise impact the Company’s public capitalization structure.
Get started
Create a free account to read the full story.